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There is some evidence that West Nile virus (WNV), which causes encephalomyelitis in equids, 13 
is an emerging disease in Europe. The aim of this study was to perform a systematic review 14 
and meta-analysis to analyse seroprevalence studies of West Nile virus in equids in European 15 
countries between 2001 and 2018. Two electronic databases, PubMed and Scopus, were 16 
searched for relevant publications published from 2001 to 2018 using predetermined 17 
keywords. A total of 1484 papers was initially found. After applying the eligibility criteria, 39 18 
papers were finally included in the systematic review. Analysis of 28,089 equids from 16 19 
European countries revealed a pooled seroprevalence of 8% (95% CI 5–12%, P<0.001, I2 = 20 
99.3%) in Europe. The pooled seroprevalence was slightly higher in Mediterranean basin 21 
countries than other countries and when calculated for samples collected between 2001 and 22 
2009 compared to 2010 to 2018. Differences in study design (e.g. sampling associated with 23 
recent outbreaks of WNV) contributed to a high degree of variability among studies. Further 24 
studies with harmonized study design and reporting of the results are recommended to better 25 
estimate and monitor European seroprevalence of West Nile virus in equids. 26 
 27 




West Nile virus (WNV) is a mosquito-borne zoonotic virus from the genus Flavivirus and family 30 
Flaviviridae (Anon, 2017). Its transmission cycle involves birds and mosquitoes, especially 31 
from the Culex species, which act as vectors of the virus. Several vertebrate species can be 32 
infected by the virus, but mammals, particularly humans and equids, are considered “dead-33 
end” hosts as they do not usually develop sufficiently high levels of viraemia for transmission 34 
to blood-feeding mosquitoes (Komar, 2000). The virus was first isolated from a human being 35 
in 1937 in the West Nile region of Uganda (Smithburn et al., 1940). Since the first reported 36 
case of West Nile virus in horses in Egypt in 1963 (Schmidt & Mansoury, 1963), the disease 37 
has expanded in range causing significant human and animal health issues. An example of 38 
these are the outbreaks reported in EU member countries since the start of the 2020 39 
transmission season and as of 10 September 2020, 173 human cases of WNV infection and 15 40 
deaths (Greece, Spain, Italy and Romania) and 60 outbreaks among equids (Spain, Italy, 41 
France, Portugal and Germany) have been reported through the European Animal Disease 42 
Notification Systemervice (ADNS).  43 
Several genetic lineages of the virus have been found, but isolates from lineages 1 and 2 have 44 
mainly been responsible for the disease in humans and equids in European countries, with 45 
lineage 1 predominant until the mid-2000s (Ciccozzi et al., 2013; Long, 2014). As a neurotropic 46 
virus causing encephalomyelitis, clinical signs in horses include ataxia, paralysis of the limbs, 47 
prolonged recumbency, muscle fasciculations, and abnormal mentation (Long, 2014). The 48 
mortality rate in horses has been estimated at 35–45% (Long, 2014). However, studies 49 
suggest that only around 10% of infected horses present neurological signs (Gardner et al., 50 
2007). For diagnosis, laboratory testing is necessary to confirm the infection as the 51 
neurological signs are not pathognomonic for the disease. Treatment is mostly supportive as 52 
there are no known effective antiviral medications (Long, 2014). An equine WNV vaccine was 53 
first licensed in the USA in 20035, and further types of WNV vaccines have since been 54 
approved for use in horses, but an equine WNV vaccine was not licensed for use in Europe 55 
until 2009. Due to the low viral titres in horses, ante mortem PCR-based detection of viral RNA 56 
is unreliable (Kleiboeker et al., 2004). Therefore, suspected cases of WNV infection are usually 57 
confirmed by IgM capture ELISA and/or measuring seroconversion using a plaque-reduction 58 
neutralization test (PRNT). Equine WNV-specific IgM antibodies are usually detectable from 59 
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around 8 days post-infection (so most horses with encephalitis test positive at the time that 60 
clinical signs are first observed) and remain detectable for up to 3 months (Beck et al., 2017). 61 
Neutralising (IgG) antibodies are detectable in equine serum by 2 weeks post-infection and 62 
can persist for more than 1 year. The OIE Terrestrial Manual (OIE, 2018) suggests that IgG 63 
indirect and competitive ELISAs, virus neutralisation test (VNT) or PRNT are suitable methods 64 
for determining prevalence of infection. However, as ELISA methods are less specific, where 65 
related flaviviruses co-circulate with WNV, positive results obtained should be confirmed by 66 
PRNT or VNT and testing against other flaviviruses in parallel. Other flaviviruses detected in 67 
Europe include Bagaza virus (BAGV), louping ill virus (LIV), tick-borne encephalitis virus (TBEV) 68 
and Usutu virus (USUV) (Llorente et al., 2015; Long, 2014).  69 
The aim of this study was to conduct a systematic review and meta-analysis to analyse the 70 
prevalence reported on  WNV studies in equids in Europe from the year 2001 to 2018 71 
inclusive, to compare the prevalence in countries of the Mediterranean basin with other 72 
European countries and to evaluate the prevalence of two periods: from 2001 to 2009 and 73 
from 2010 to 2018.  74 
Materials and methods 75 
Search strategy  76 
A systematic search strategy was performed in the databases PubMed and Scopus to identify 77 
all published studies reporting the prevalence of WNV in equids in Europe from 1 January 78 
2001 to 20 March 2019 (the date the search was performed). The following key words and 79 
Boolean operators (“AND” and “OR”) were used:  (prevalence OR incidence OR frequency OR 80 
occurrence OR detection OR identification OR isolation OR characterization OR investigation) 81 
AND (WNV OR West Nile virus OR Flavivirus) AND (horse OR equine OR equid OR donkey OR 82 
mule OR foal). In Scopus, the search terms were applied to the title, abstract and the 83 
keywords. In PubMed, the search terms were applied in all fields. No language restrictions 84 
were applied. Retrieved searches were entered into a Microsoft Excel (2018) file. 85 
The reference lists of the selected publications were reviewed manually to identify all 86 
potential studies that could have been missed in the two databases. 87 
Eligibility criteria  88 
Inclusion criteria were divided into two categories: inclusion criteria related to the literature 89 
search and inclusion criteria inherent to the studies. First, the studies had to be published 90 
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between 1 January 2001 and 20 March 2019 and the full text had to be available in English, 91 
Spanish or French. In addition, studies had to be prospective or retrospective serosurveys 92 
with animal level prevalence and animals of the genus Equus (excluding zebra) reported, 93 
carried out in a European country and have performed a VNT and/or PRNT to confirm the 94 
specificity of antibodies detected by ELISA. 95 
Studies were excluded if the titles and abstracts were not relevant to the subject of interest, 96 
did not fulfil the above eligibility criteria, had data missing or duplicated data published in 97 
another included study. 98 
Study selection and data extraction 99 
In the first screening of all searched studies, duplicates were eliminated. The titles and 100 
abstracts of all retrieved studies were then independently screened by two authors (MBCM 101 
and MB) to identify potentially relevant studies. When the study could not be assessed from 102 
the title and abstract, the full text was screened. The full text of the studies retained after the 103 
first screening were further scanned independently and in a standardized manner by two 104 
authors (MBCM and MB) applying the eligibility criteria.  105 
After the eligibility assessment process, data were extracted independently by two authors 106 
(MBCM and MB) and classified in three categories: general data related to the study, data 107 
related to the diagnostic techniques and data related to the animals. Any disagreements that 108 
arose between the authors was resolved through discussion with a third author (JMD). All the 109 
extracted data were summarized in a Microsoft Excel (2018) file. 110 
The general data related to the study were: title, first author’s name, name of the journal, 111 
year of publication, database where the study was identified (PubMed or Scopus), type of 112 
study (i.e. prospective or retrospective serosurvey), language, country and region, sampling 113 
protocol (e.g. convenience or random sample), year and season of testing. The data related 114 
to the diagnostic techniques were: initial serological test to detect the presence of antibody 115 
(immunoglobulin G), type of confirmatory test, strain of the confirmatory test and additional 116 
serological tests performed. The data related to the animals included: number of equids, 117 
mean age, sex, breed, vaccination, clinical signs.   118 
The total number of equids tested and the number testing positive specifically for WNV 119 
antibodies (and without a reported history of vaccination) were also extracted independently 120 
by two authors (JMD and OTO) and any disagreement confirmed by a third author (MB). 121 
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Data analysis and presentation 122 
Statistical meta-analysis of the proportion of WNV antibody-positive animals was conducted 123 
and a forest plot generated using metaprop in STATA 16 (Nyaga et al., 2014). Subgroup meta-124 
analysis was done for the Mediterranean and non-Mediterranean countries of Europe to 125 
investigate if greater prevalence was reported in Mediterranean countries where the climate 126 
is more favourable for mosquitoes. As well, analysis of two balanced 9-year-period subgroups 127 
(2001-2009 and 2010-2018) were performed. This allowed the impact of the introduction of 128 
a WNV vaccine on seroprevalence studies to be determined. Estimates from individual studies 129 
were transformed using the Freeman-Tukey double arcsine transformation to stabilize the 130 
variance. Heterogeneity was assessed using the I squared statistic (I2). A funnel plot to assess 131 
publication bias was generated and outliers identified using R (R Core Team, 2014).   132 
Maintenance of study standard 133 
This study has been performed in accordance with guidelines for meta-analysis of 134 
observational studies (MOOSE statement) and preferred reporting items for systematic 135 
reviews and meta-analyses (PRISMA statement) (Moher et al., 2015; Stroup et al., 2000). 136 
Results 137 
Search results and study selection  138 
From the initial database search, 1484 potentially relevant publications were identified of 139 
which 663 were found in Scopus and 821 in PubMed. After removing the duplicates, the title 140 
and abstract of 950 studies were screened. Of the 104 studies that remained, 65 studies were 141 
excluded for reasons listed in Figure 1. The lack of a confirmatory test to measure neutralising 142 
antibodies was one of the main reasons for exclusion (n=13). The other exclusion factors 143 
were: review articles, type of study, language other than English, French or Spanish, 144 
insufficient data, full text not available, duplicated data, type of study and year of study. 145 
Finally, a total of 39 publications satisfied the inclusion criteria and were included in the 146 
systematic review, of which 38 were in English and one in French. Of the 39 publications, 3 147 
were found in Scopus, 8 in PubMed and 28 in both databases. No additional studies that 148 
satisfied the inclusion criteria were found in the reference lists of selected studies. Table 1 149 
presents the studies included in the systematic review.  150 
Study characteristics 151 
7 
 
Of the 39 studies included in the systematic review, the majority (n=36) were prospective 152 
serosurveys; 3 studies were retrospective. In 14 studies (35.9%), it was stated that the equine 153 
serum samples were taken randomly. It was assumed that in the other studies, convenience 154 
samples were obtained. In total, 28,089 equids were tested, of which 375 were donkeys or 155 
mules. The prevalence was described only in horses in 34 studies, only in donkeys and mules 156 
in one study (García-Bocanegra et al., 2012c) and in both horses and donkeys in 3 studies 157 
(Bosiljka et al., 2013; Ozkul et al., 2013; Raleigh et al., 2012) The mean number of equids 158 
sampled in each study was 720 with a wide range (68 to 5178). 159 
Of the 16 European countries in which studies were conducted, 7 (Albania, Croatia, Spain, 160 
France, Italy, Portugal and Turkey) are part of the Mediterranean basin (Figure 2). The highest 161 
number of studies was found for Spain (n=9), followed by France and Serbia (n=4). Prevalence 162 
data were available for both date ranges in the following ten countries: Croatia, Czech 163 
Republic, France, Germany, Ireland, Poland, Portugal, Serbia, Spain and Turkey (34 studies). 164 
Twelve of the studies were carried out in the first date range (2001–2009) and 19 in the 165 
second period (2010–2018). In one study (Raleigh et al., 2012), prevalence data were 166 
separated in the two periods of time. There were five studies that started in the first period 167 
and finished in the second period and two for which the year(s) of sampling was not specified.  168 
In the majority of studies (n=24), samples were first screened by ELISA and some or all of the 169 
positive-testing samples were confirmed by testing for WNV-specific neutralising antibodies. 170 
In 10 studies, a neutralisation test was performed without prior screening by ELISA and in one 171 
study both ELISA and VNT were used to screen the samples. In three studies, the initial 172 
screening test was either agar gel immunodiffusion (AGID), immunofluorescence antibody 173 
test (IFAT), or multiplex immuno-assay (MIA). Additional tests performed included western 174 
blot and haemagglutination inhibition (HI) test.  175 
The virus strain used for the VNT or PRNT was described in 24 studies. The strain ‘Eg101’ was 176 
used in 12 studies, ‘New York (NY99)’ in 7 studies and ‘Israel 1998 (IS98-ST1)’ in one study. 177 
These three strains belong to genetic lineage 1. Only five studies used genetic lineage 2 178 
strains: ‘Austrian’ (n=3), ‘Hungary 578/2010’ (n=1) or unspecified (n=1). Of the five studies 179 
that used genetic lineage 2 strains, one study also used a strain from genetic lineage 1. The 180 
remaining studies (n=15) did not specify the strain used.  181 
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In 18 of the 39 studies, samples were additionally screened for neutralising antibodies to 182 
other flaviviruses; TBEV only in 2, USUV only in 6, USUV and TBEV in 9 and Bagaza virus in 1.  183 
Positive titres were detected against TBEV or USUV in five and seven studies, respectively. In 184 
four studies, some samples had similar titres against both WNV and USUV. 185 
Of the 39 selected studies, only 3 described minimal demographic data (age, sex, breed) and 186 
8 reported whether or not any of the tested equids were vaccinated or showed any clinical 187 
signs. 188 
More than half of the studies (n=23) reported the season of year when the animals were 189 
sampled; the majority of the studies were carried out in autumn (September to November). 190 
Meta-analysis of West Nile virus seroprevalence  191 
The pooled seroprevalence was 8% (95% CI 5–12%) with substantial heterogeneity (I2 = 192 
99.3%) (Figure 3). Pooled seroprevalence was slightly higher in Mediterranean (9%, 95% CI 5–193 
14%) than non-Mediterranean countries (7%, 95% CI 3–14) and in the first sampling period 194 
(8%, 95% CI 2–17%) than in the second sampling period (7%, 95% CI 4–10%) (Table 2). A funnel 195 
plot (Figure 4) did not identify significant publication bias. However, two studies (Calistri et 196 
al., 2010; Petrović et al., 2014) were identified as outliers in the Studentized residual test.  197 
Discussion 198 
This systematic review sought to highlight important trends in WNV seroprevalence in equids 199 
in Europe; prevalence data of WNV reported in 39 studies of equids in Europe were analysed 200 
from the year 2001 to the year 2018. The pooled seroprevalence obtained was 8% (95% CI 5–201 
12%). However, few studies reported using random sampling methods, therefore caution 202 
must be applied when generalising the seroprevalence estimates to the target population. 203 
The substantial heterogeneity (I2 = 99.3%) meant that meaningful conclusions could not be 204 
drawn about differences in seroprevalence between Mediterranean and non-Mediterranean 205 
countries of the two periods evaluated.  206 
There was no evidence that small studies with small effect sizes were missing. However, the 207 
two studies that were identified as outliers (Calistri et al., 2010; Petrović et al., 2014) were 208 
also the two studies with the highest seroprevalence: 39% and 49%, respectively. The study 209 
by Calistri et al. (2010) was associated with investigation of an outbreak of WNV. Similarly, in 210 
the study by Petrović et al. (2014), samples were collected from horses in November and 211 
December 2012 after the first human outbreak of WNV reported in Serbia, which started in 212 
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August 2012. Other studies with high seroprevalence were also associated with recent 213 
outbreaks. 214 
The quality of data reporting varied between studies, for example, only three studies provided 215 
information on animal characteristics such as age, sex and breed, each of which could 216 
influence risk of exposure to and/or susceptibility to WNV infection for example, older 217 
animals are more likely to have been exposed to virus. Reporting these demographic data is 218 
important for comparisons are to be made between the outcomes of different studies. 219 
Recruitment criteria are important in understanding disease transmission in mobile animal 220 
populations such as horses where animals may have been exposed to the virus somewhere 221 
other than the study location. Furthermore, vaccination status became important after an 222 
equine WNV vaccine was first licensed in Europe in 2009. For example, Ziegler et al. (2012) 223 
found four samples positive for WNV antibodies in a study conducted in Germany, but three 224 
of these were from vaccinated horses (and were therefore removed from the seroprevalence 225 
estimation in this study) and one was from a horse from Hungary. However, vaccination status 226 
was only reported in 8 studies although 19 were conducted on samples collected after 2009. 227 
ELISA is often the assay of choice for conducting seroepidemiological studies because it is 228 
simple, sensitive, rapid and often commercially available. However, due to extensive cross-229 
reactivity between antibodies raised against different flaviviruses, the ELISA can yield false 230 
positive results where different flaviviruses co-circulate (Beck et al., 2013). Therefore, this 231 
systematic review only included studies that used virus / plaque reduction neutralisation tests 232 
to confirm positive samples, however 21 out of 39 studies did not test in parallel other 233 
flaviviruses, which could have introduced errors in their prevalence estimation. The issue of 234 
cross-reactivity in ELISA was illustrated in some of the studies, for example Berxholi et al. 235 
(2013) found that two of seven samples that were positive in ELISA but negative in WNV VNT 236 
were positive for TBEV antibodies. Similarly, Ziegler et al. (2013a) found that four samples 237 
that were positive by ELISA but negative by WNV VNT were positive for TBEV (but not for 238 
USUV). One of the included studies (Lupulovic et al., 2011) was the first to report neutralising 239 
antibodies to USUV in horses, however, as the PRNT titres were 120 and 90 for WNV and 240 
USUV, respectively, they were not able to conclude whether this represented cross-reactive 241 
antibodies or prior exposure to both viruses. Calistri et al. (2010) mention that USUV was 242 
circulating in Italy in the year before samples were obtained in their study, but they did not 243 
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test for USUV antibodies. In most cases, neutralisation tests were positive for one virus only 244 
or titres were markedly higher (e.g. at least 2-fold) for one virus. However, neutralisation tests 245 
were not always discriminatory, particularly where VNT titres were low (Jiménez-Clavero et 246 
al., 2007). Furthermore, Vanhomwegen et al. (2017) concluded that of 21 samples that were 247 
positive for flavivirus antibodies, 11 were specifically positive for WNV, 2 for USUV and 1 for 248 
TBEV while 8 were positive for an unidentified flavivirus (1 of which they reported as positive 249 
for both WNV and an unidentified flavivirus). Ziegler et al. (2013a) reported four samples that 250 
were positive by WNV ELISA but VNT negative with WNV and USUV, whichalthough this could 251 
also be related with due to the lower sensitivity of VNT compared to ELISA (Beck et al., 2017). 252 
Furthermore, a high prevalence of tick-borne encephalitis virus (TBEV) has been reported in 253 
other studies in some European countries (Rushton et al., 2013). Therefore, there is evidence 254 
of non WNV flaviviruses circulating in Europe, which should be taken into account when 255 
performing a serosurvey study. 256 
Although most studies did not specify if seropositivity was caused by lineage 1 or 2 WNV 257 
strains, this is probably not critical, because it is not possible to tell by which virus lineage the 258 
immune response was elicited as the two strains differ only in three amino acids within 259 
domain III of the E protein, against which most neutralizing antibodies are directed (Berxholi 260 
et al., 2013). 261 
Most studies were performed in autumn, probably after the beginning of the transmission 262 
season and occurrence of outbreaks in the summer. This should not affect the results of the 263 
meta-analysis other than the already mentioned bias caused by association of a serosurvey 264 
study after regional outbreaks, which could falsely increase the prevalence estimation. 265 
Despite the fact that WNV transmission and outbreaks in equids occurs in EU countries, the 266 
limitations detected in this study precluded the evaluation of an increase in seroprevalence 267 
over time. An analysis of the number of reported outbreaks could be useful to determine the 268 
re-emerging status of this virus, however this was not the scope of this study. 269 
Horses have been suggested as useful sentinels for WNV surveillance. However, the true 270 
seroprevalence of WNV in European equids remains uncertain due to variation in study design 271 
and reporting, and difficulty discriminating between cross-reactive antibodies. Standardised 272 
seroprevalence studies are critical to better understand the current epidemiological status of 273 
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Table 1. Characteristics of studies included in the systematic review 





Screening test Tests for other 
flaviviruses 
1. Abad-Cobo et al. 2017 Spain (ES) 5 369 1.36 2011–2013 ELISA USUV 
2. Alba et al. 2014 Spain (ES) 0 178 0 2011 ELISA  
3. Bakonyi et al. 2013 Hungary (HU) 79 276 28.62 2009 IFAT  
4. Barbić et al. 2012 Croatia (HR) 72 2098 3.43 2010–2011 ELISA TBEV + USUV 
5. Barbić et al. 2013 Croatia (HR) 48 1380 3.48 2011 ELISA TBEV + USUV 
6. Barros et al. 2011 Portugal (PT) 40 1313 3.05 2004–2010 ELISA  
7. Barros et al. 2017 Portugal (PT) 18 989 1.82 2011–2016 ELISA  
8. Bażanów et al. 2018 Poland (PL) 62 411 15.09 2012–2013 VNT USUV 
9. Berxholi et al. 2013 Albania (AL) 37 167 22.16 N.S. ELISA & VNT TBEV 
10. Bosiljka et al. 2013 Serbia (RS) 45 11992 3.75 2008–2012 AGID  
11. Busani et al. 2011 Italy (IT) 348 2528 13.77 2008 & 2009 ELISA TBEV + USUV 
12. Busquets et al. 2019 Spain (ES) 9 138 6.52 2017 & 2018 ELISA BAGV 
13. Cabre et al. 2005 France (FR) 0 94 0 2003 ELISA  
14. Calistri et al. 2010 Italy (IT) 794 2030 39.11 2008 PRNT  
15. Csank et al. 2018 Slovakia (SK) 10 145 6.90 2013 ELISA TBEV + USUV 
16. Durand et al. 2005 France (FR) 304 906 33.55 2003 ELISA  
17. Ergunay et al. 2014 Turkey (TR) 48 389 12.34 2011–2013 PRNT  
18. García-Bocanegra et al. 2012a Spain (ES) 36 510 7.06 2010 ELISA  
19. García-Bocanegra et al. 2012b Spain (ES) 12 109 11.01 2010–2011 ELISA  
20. García-Bocanegra et al. 2012c Spain (ES) 12 1653 7.27 2011 ELISA  
21. Hubálek et al. 2008 Poland (PL) 0 78 0 2006 PRNT USUV 
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22. Hubálek et al. 2013 Czechia (CZ) & 
Slovakia (SK) 
19 395 4.81 
2008–2011 
PRNT TBEV + USUV 
23. Jiménez-Clavero et al. 2007 Spain (ES) 13 157 8.28 2005 VNT USUV 
24. Jiménez-Clavero et al. 2010 Spain (ES) 0 68* 0 2008 VNT USUV 
25. Lupulovic et al. 2011 Serbia (RS) 42 349 12.03 2009–2010 ELISA USUV 
26. Madić et al. 2007 Croatia (HR) 4 980 0.41 2010–2011 ELISA  
27. Maquart et al. 2017 France (FR) 9 96 9.38 2014 ELISA USUV 
28. Medić et al. 2014 Serbia (RS) 72 252 28.57 2007–2011 ELISA  
29. Monaco et al. 2010 Italy (IT) 271 770 35.19 2008 VNT TBEV + USUV 
30. Ozkul et al. 2006 Turkey (TR) 36 2994 12.04 N.S. PRNT  
31. Ozkul et al. 2013 Turkey (TR) 57 180 31.67 2011 PRNT  
32. Petrović et al. 2014 Serbia (RS) 64 130 49.23 2012 ELISA  
33. Pradier et al. 2014 France (FR) 143 1159 12.34 2007–2008 ELISA  
34. Raleigh et al. 2012 Ireland (IE) 0 4905 0 2005–2006 (n=90) 
& 2010 (n=400)  
ELISA  
35. Vanhomwegen et al. 2017 Spain (ES) 11 172 6.40 2011–2012 MIA TBEV + USUV 
36. Weissenböck et al. 2003 Austria (AT) 0 350 0 2001 PRNT  
37. Ziegler et al. 2012 Germany (DE) 1 1282 0.08 2007–2009 ELISA TBEV + USUV 
38. Ziegler et al. 2013a Germany (DE) 2 5178 0.04 2010–2012 ELISA TBEV + USUV 
39. Ziegler et al. 2013b Ukraine (UA) 42 310 13.55 2010–2011 ELISA TBEV 
1Two letter ISO country code 
N.S., not specified 
AGID, agar gel immunodiffusion; IFAT, immunofluorescence antibody test; ELISA, enzyme-linked immunosorbent assay; MIA, multiplex immuno-
assay; PRNT, plaque reduction test; VNT, virus neutralization test. 
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BAGV, Bagaza virus; TBEV, tick-borne encephalitis virus; USUV, Usutu virus 
21133 horses and 66 donkeys; 382 donkeys and 83 mules; 4259 horses and 40 mules; 5386 horses and 104 donkeys 




Table 2. Pooled seroprevalence of WNV in Europe  






D.F. I2 (%) 
Region Mediterranean 2327 17,244 9 (5–14) 24 99.1 
 Non-Mediterranean 438 10,845 7 (3–14) 13 99.0 
Sampling period 2000–2009 1953 9788 8 (2–17) 12 99.4 
 2010–2018 521 14,327 7 (4–10) 19 98.3 
       







Figure 1. Flow diagram of article selection for West Nile prevalence in equids in Europe 
Figure 2. Map showing European countries for which data were included in the systematic 
review. Created using https://mapchart.net/europe.html with different colour shading used 
for Mediterranean and non-Mediterranean countries and depth of shading indicating number 
of studies performed in each country. 
Figure 3. Forest plot showing the pooled estimated seroprevalence (ES) of West Nile virus 
among equids in Europe. Horizontal lines represent 95% confidence intervals (Cls). Each 
square box denotes the seroprevalence rate point estimate and the area is proportional to 
the weight of the study.  
Figure 4. Funnel plot of standard error by Freeman-Tukey double arcsine transformed 
proportion for all studies (n=39) 
 
 
